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Regulation of the immune response by the third component of complement  (C3) 
has been extensively investigated. C3 and the cleavage products C3b, C3c, and C3d 
have each  received  considerable attention  in  studies  of lymphocyte activation and 
regulation (1-12). Receptors for fragments of C3--such as C3b, C3c, and C3d--have 
been detected on a number of  cells including lymphocytes and macrophages. However, 
the biological significance of  these receptors remains unknown. C3 has been implicated 
in the activation of macrophages (8) and in modulation of cellular immune functions 
(1-17).  Most of these biological activities have been attributed  to C3b, C3c, or C3d 
with little or no activity associated with the C3a fragment (5, 7). 
The C3a fragment has anaphylatoxin properties as evidenced by its  potent spas- 
mogenic and tachyphylactic action (17). More recently, Needleman et al. (18) reported 
that  in  a  serum-free environment, a  C3  fragment,  presumably C3a,  suppresses  the 
antigen-  and  mitogen-induced  proliferative  responses  of human  peripheral  blood 
lymphocytes (PBL).  Normal control of C3a action  is  governed by a  serum enzyme 
(17).  Interaction  of C3a with  endogenous carboxypeptidase N  results  in  the  rapid 
cleavage of the terminal  arginine from C3a producing C3ades Ars-77. The des Arg-77 
derivative of C3a is incapable of inducing anaphylactic reactions (19). 
In this report we have assessed  the ability of C3a to modulate both specific and 
nonspecific immune responses. The anti-sheep erythrocyte (SRBC) responses of both 
human  PBL  and  murine  splenocytes  were  suppressed  by  C3a.  The  nonspecific 
polyclonal response system mediated by Fc fragments was chosen to determine the 
cellular  level  at  which  C3a  suppression  occurs.  Both  macrophages  (20-22)  and 
thymus-derived  (T)  cells  (22-24)  are  an  integral  part  of this  response.  The results 
presented  in  this  report  indicate  that  C3a  is  a  potent  suppressor  of specific  and 
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nonspecific humoral  immune responses and  its action is at the level of the helper T 
cell. 
Materials  and  Methods 
Source of PBL.  Venous  blood  was  collected  in  heparinized  Vacutainer  tubes  (Becton, 
Dickinson & Co., Rutherford, N  J) from healthy adult donors of both sexes. 
Animals.  Male mice of the C57BL/6  strain were obtained from The Jackson Laboratory 
(Bar Harbor, ME). BALB/c mice were obtained from Scripps Clinic and Research Foundation 
breeding colony (La Jolla, CA). All mice were between 8 and  15 wk of age when used. 
BCL~.  The in vitro line of BCL1  was a  generous gift from Dr. Samuel Strober Stanford 
University (Stanford, CA) and its properties have been extensively described (25-27). 
Preparation of Fc Fragments.  A human IgG myeloma protein (F1) was a gift from Dr. Hans L. 
Spiegelberg, Research Institute of Scripps Clinic. Fc fragments were obtained by digestion of 
IgG1 with papain (Sigma Chemical Co., St. Louis, MO) in the presence of L-cysteine (Sigma 
Chemical Co.) and EDTA (J. T. Baker Chemical Co., Phillipsburg, NJ)  for 5 h  (28).  The Fc 
and Fab fragments were separated from each other by DEAE chromatography (29). 
Preparation of Plasmin _Pc Fragments.  Plasmin (Sigma Chemical Co.)  digestion of the FIgGI 
protein was carried out for 24 h (30). The digested IgG was resolved into two peaks by Sephadex 
G-150 (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N  J) chromatography. 
The small molecular weight peak has been previously shown to polyclonally activate murine B 
cells in the absence of macrophages (21). 
Preparation of Complement Components.  Human C3a was isolated from complement-activated 
serum containing the carboxypeptidase N  inhibitor 2-mercaptomethyl-5-guanidinopentanoic 
acid at 1 mM (19). The isolation procedure has been described in detail (31, 32). The des Arg 
form of C3a was prepared from complement-activated serum by exactly the same procedure as 
described for C3a except that no carboxypeptidase inhibitors were employed. These complement 
products were judged homogenous by single-banding patterns on cellulose acetate electropho- 
resis at pH 8.6 and by amino acid composition. Human C3a prepared in this manner contains 
<0.1% contaminating C4a or C5a as determined by radioimmunoassay (33). 
Preparation of PBL.  Heparinized peripheral blood was diluted with  2  vol of phosphate- 
buffered saline (PBS):0.001  M  phosphate pH 7.2, 0.15  M  NaCI. Lymphocytes were separated 
by Ficoll-Paque (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc.) gradient centrifugation 
as described previously (34). 
Isolation of Peripheral Blood B and T Cells.  PBL suspensions were enriched for B and T ceils by 
the neuraminidase-treated SRBC rosette technique (34). The nonrosetting cells were defined as 
B cell-and-monocyte-enriched (34)  and the rosetting cells as T  cell-enriched (34).  The T  cell 
populations were subjected to  2,000 rad of irradiation (Gamma Cell 40;  Atomic Energy of 
Canada Ltd., Ottawa) before use in the in vitro antibody response cultures. 
Enrichment of T Lymphocytes.  The spleen cell population was enriched for T cells by filtrati6n 
through nylon wool columns (Fenwal Laboratories, Deerfield, IL) (35). 
Anti-Lyt Antiserum Treatment.  Anti-Lyt 2.2  was obtained from  Dr.  F. W. Shen,  Memorial 
Sloan-Kettering Cancer Center,  New  York.  Antisera and  complement  treatment  were  per- 
formed as described previously (23). 
Depletion of Macrophages.  Spleen  cells were  filtered through  columns  of Sephadex  G-10 
(Pharmacia Fine Chemicals) by the method of Ly and  Mishell (36)  as described previously 
(21). 
Murine Lymphocyte Response Assays 
PROLIFERATION TO FC FRAGMENTS.  2 ×  105 BCL1 cells were cultured in 0.2 ml RPMI  1640 
(Flow Laboratories, Inc.,  Rockville MD),  supplemented with  2  mM  L-glutamine,  1%  BME 
vitamins  (Grand  Island  Biological Co.,  Grand  Island,  NY),  100  U  penicillin, and  100  /tg 
streptomycin (Microbiological Associates, Bethesda, MD). The BCLx cells were added to wells 
of flat-bottomed microtiter plates (3042 Microtest II; Falcon Labware, Div. of Becton, Dickinson 
& Co., Oxnard, CA) to which 2 X  105 irradiated (1,000 rad) BALB/c spleen cells had been 
allowed to adhere. The cultures were pulsed with  1 ~Ci tritiated thymidine ([aH]TdR)  5 Ci/ 1414  ANAPHYLATOXIN-MEDIATED REGULATION OF  HUMAN  RESPONSE 
mM  (Amersham-Searle,  Arlington  Heights, IL)/0.025  ml after  1 d  of culture  and  harvested 
~24  h  later with an automated  cell harvester  (M 24V;  Brandel,  Rockville, MD).  The filters 
were dried, placed in 3 ml scintillation fluid, and counted on a scintillation counter. 
PROLIFERATION TO BACTERIAL  LIPOPOLYSACCHARIDE  (LPS).  The response of the BCL1 B cell 
tumor line to Escherichia coli LPS (055:B5;  Difco Laboratories, Detroit, MI) was measured the 
same as the proliferative response to Fc fragments except no macrophages were mixed with the 
BCL1 cells. 
POLYCLONAL ANTIBODY  RESPONSE  TO  FC FRAGMENTS.  The Fc fragment-mediated  polyclonal 
antibody response was done as previously described (22).  Briefly, 6 X  10  s spleen cells in 0.3 ml 
RPMI  1640  supplemented  with  2  mM  L-glutamine,  1%  BME  vitamins,  5  ×  10  -5  M 
2-mercaptoethanol (2-ME), antibiotics, and 7.5% fetal calf serum (Gibco Laboratories). Cultures 
were harvested on day 3 and the response to 2,4,6-trinitrophenyl  (TNP) was measured by slide 
modification  of the Jerne  and  Nordin  plaque  assay  (37).  Results  of the  plaque  assay  are 
expressed as mean PFC/106 original cells of duplicate pools +  SE. 
IN  VITRO ANTI-SRBC RESPONSE.  Spleen  cells  were  removed  from  mice  that  were  injected 
intraperitoneally  with  0.1  ml  of  10%  suspension  of SRBC  4-6  wk  previously.  A  modified 
Mishell-Dutton  culture  system was employed  for the generation  of antibody-producing  cells 
(38,  39). 6 X  105 cells in 0.3 ml RPMI  1640 supplemented as described above with the addition 
of 5  ×  10  -5 M  2-ME and  7.5%  FCS were cultured  for 4 d  in flat-bottomed microtiter plates. 
The direct anti-SRBC response was measured by the slide modification of the Jerne and Nordin 
plaque assay  (37).  The results are recorded as direct anti-SRBC PFC/10 s original cells +  SE. 
Human Lymphocyte Response Assays 
POLYCLONAL ANTIBODY RESPONSE TO Fc FRAGMENTS.  The protocol used has been described 
in detail previously (34).  Briefly, 1 ×  105 B cell-enriched (E-) cells were cultured with 2 ×  105 
T  cell-enriched  (E  +)  cells in 0.3  ml  RPMI  1640  supplemented  with  2  mM L-glutamine,  1% 
BME vitamins, antibiotics, and  10% FCS. The number of immunoglobulin-secreting cells was 
determined 6 d later by the protein A plaque assay (34).  Amplifying sera in the protein A assay 
recognized human IgG +  IgM +  IRA. The results are recorded as Ig-secreting cells/10  s original 
B cells +  SE. 
IN VITRO ANTI-SRBC RESPONSE.  The primary anti-SRBC response was done as described by 
Misiti and Waldmann  (40).  5 X  l0  s PBL were cultured in  1 ml RPMI  1640 supplemented  as 
described for the Fc polyclonal assay plus 5 X  10  -5 2-ME, and the SRBC-adsorbed autologous 
human plasma was substituted for the FCS. The cultures were maintained in gas boxes, which 
were rocked at  7 or 3.5 cycles/min for  11  d. The cultures were fed a  Mishell-Dutton cocktail 
mixture  (38)  containing autologous plasma every other day.  The direct or IgM response was 
measured by the Jerne and Nordin plaque assay on day 11 of culture. The results are recorded 
as direct anti-SRBC PFC/culture +  SE. 
ANTIGEN-INDUCED PROLIFERATIVE  RESPONSE.  The proliferative response to tetanus toxoid was 
done as described by Broffet al. (41).  Briefly, 1 X  l0  b PBL were cultured with 5/~g/ml tetanus 
toxoid  (Department  of Public  Health,  Boston,  MA).  The  response  was  assayed  on  day  7 of 
culture. 
MITOGEN-INDUCED  PROLIFERATIVE  RESPONSE.  The  mitogen proliferative response was  done 
the same as the antigen proliferative response. Pokeweed mitogen (PWM) (Calbiochem-Behring 
Corp., American Hoechst Corp., La Jolla, California) was used at a concentration of 33/.tg/ml 
and  phytohemagglutinin  (PHA-P)  (Difco Laboratories,  Detroit,  MI)  was  used  at  1%.  The 
response was assayed on day 5 of culture. 
Results 
C3a-mediated  Suppression of Both  Specific  and  Polyclonal Antibody  Response by  Human 
PBL.  Addition  of purified  human  C3a  to  cultures  of PBL caused  a  suppression  in 
the  ability  of  these  cells  to  produce  polyclonal  antibody  when  stimulated  by  Fc 
fragments derived from human  Ig (Fig.  1). Maximum  suppression  (84%) was achieved 
with  C3a  at  50  /~g/ml.  In  contrast,  C3adesArg-77  (C3a  minus  the  carboxy-terminal 
arginine)  at concentrations up to 200/~g/ml  (Fig.  1) was ineffective in suppressing the EDWARD  L.  MORGAN,  WILLIAM  O.  WEIGLE,  AND  TONY  E.  HUGLI  1415 
1800- 
,~ 1600  ~ 
+l 
_~  14oo- 
0= 1200- 
I000- 
800-  ==, 
600- 
r~  400-  .._= 
200- 
0'.1  f.o  5'0 160 200 
100- 
"~'~ 25-7550 
0  0.1 1.0  50  100200 
p glml 
Fxo.  1.  Human PBL (1 X  105 B and 2 X  l0  s T  ceils)  were cultured with 5 btg/ml of Fc fragments 
and  increasing amounts of C3a  (0)  or C3aa= ^r~-77 (O)-  The  polyclonal  antibody  response was 




~  100" 
80- 
60- 
co  .=  40- 
= 
~=  20- 






0111101'0  50 
/a g/ml 
FIc.  2.  Human PBL (5 ×  10  n) were cultured with 1 X  l0  s SRBC and increasing amounts of C3a 
(0) or C3adesArg-77 (Q)). The direct anti-SRBC response was measured on day  11 of culture.  1 mM 
2-mercaptomethyl-5-guanidinopentanoic acid was present. 
polyclonal  antibody  response.  We  also  examined  whether  C3a  suppressed  specific 
antibody responses. Human C3a was added to cultures containing PBL and SRBC in 
an attempt to suppress the primary in vitro anti-SRBC response. The results depicted 
in Fig. 2 reveal that C3a also suppresses specific antibody responses. The addition of 
10  ~g/ml  C3a  to  cultures  results  in  ~100%  suppression.  When  C3adesArg-77  was 
substituted for C3a, no suppression was observed, indicating that the terminal arginyl 
residue is essential for suppression of both specific and nonspecific antibody responses 
by human PBL. 
Inability  of C3a to Suppress T and B Cell-mediated Proliferative Responses.  To assess the 
effect of C3a on specific T  cell proliferative responses, human PBL were stimulated 
with tetanus toxoid. The results in Fig. 3 indicate that addition of C3a to culture does 
not suppress this response. To further explore the action of C3a on T cell proliferation, 
stimulation  of T  cells  by nonspecific  mitogens was examined  in  the  presence  and 
absence of C3a.  Neither C3a or C3aae8 ~g-77 were capable of suppressing the T  cell 
response to PHA or the T  and B cell proliferative response to PWM  (Table I). 
In  addition  to  being  a  potent  polyclonal  activator,  Fc  fragments  induce  both 
murine  (20)  and human  (34)  B cells to proliferate. To assess the effects of C3a on B 
cell proliferation, C3a was added along the Fc fragments to murine spleen cell cultures 1416  ANAPHYLATOXIN-MEDIATED  REGULATION  OF  HUMAN  RESPONSE 
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Fro.  3.  Human PBL (1 x  l0  b) were cultured with 5/zg/ml tetanus toxoid and 50 #g/ml C3a. The 
proliferative response was measured on day 7 of culture.  1 mM 2-mercaptomethyl-5-guanidinopen- 
tanoic acid was present. 
TABLE  I 
Inability of C3a to Suppress the PHA- and PWM-induced  Proliferative 
Responses by Human PBL 
Suppres- 
Stimulator  C3a  C3ades  Arg-77*  [aH]TdR uptake  sion 
cpm/culture ± SE  % 
--  -  -  2,432 ±  486  -- 
PHA:~  -  -  187,750 ±  5,289  0 
PHA  +  -  175,502 +  1,800  6 
PHA  -  +  175,154 ±  5,660  6 
PWM§  -  -  41,243 ±  256  0 
PWM  +  -  39,612 +  180  3 
PWM  -  +  36,407 +  3,821  10 
* Both C3a and C3ades Arg-77 were present at  a 
ml. 2-mercaptomethyl-5-guanidinopentanoic 
1: PHA was 1%. 
§ PWM was 33/~g/ml. 
final concentration of 100 #g/ 
acid was  1 mM. 
TABLE  II 
Inability of C3a to Suppress the Fc Fragment-mediated Proliferative Response 
of Murine Spleen Cells 
Fc*  C3a:~  [3H]TdR uptake  Suppression 
cprn/culture ± SE  % 
--  --  12,652  _. 2,194  -- 
+  -  40,312 +  749  0 
+  +  36,135 :t: 2,489  10 
* 250/.tg/ml of Fc added. 
50/~g/ml of C3a added.  2-mercaptomethyl-5-guanidinopentanoic acid was 
1 mM. 
and  the  proliferative  response  measured.  The  results  in  Table  II  show  that  B  cell 
proliferation  is unaffected  by  C3a. 
C3a-mediated  Suppression  of Both  Specific  and  Polyclonal  Antibody  Responses  by  Murine 
Splenic Lymphocytes.  We  questioned  whether  human  C3a  could  suppress  the humoral 
immune  response  in  a  more  defined  model.  Therefore,  murine  lymphocytes  were 
examined  for specific anaphylatoxin  effects.  Human  C3a  at  50 #g/ml  suppressed  the 
Fc polyclonal  antibody  response  of murine  cells to approximately  the  100%  level  (Fig. 
4).  In  contrast,  addition  of C3ades Arg-77 to  the culture  produced  little,  if any,  suppres- 
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FIe. 5.  Murine splenic lymphocytes (6 ×  105) were cultured with  1 ×  106 SRBC and increasing 
amounts of C3a (0) or C3ad~,  A,~-77 (O). The direct anti-SRBC response was measured on day 4 of 
culture.  1 mM 2-mercaptomethyl-5-guanidinopentanoic  acid was present. 
dependent  manner,  whereas C3adesArg-77  failed to produce a  significant suppression 
even at very high concentrations  (Fig. 5).  The main difference between the effect of 
C3a on the human and murine models was the concentration of human  C3a needed 
to produce 50% suppression. Suppession of the murine humoral immune response to 
the 50% level required -  100-fold greater quantities of human C3a (0.1  vs.  10 ~g/ml) 
than  were  needed to achieve the same level of suppression  in  the human  response. 
This difference indicates that there is better binding of human C3a to receptor sites 
on  homologous cells than  heterologous cells.  Such  species differences were  not  dis- 
cerned for the anaphylatoxin activities of human, rat, and porcine C3a (17). 
Kinetics of C3a-induced Suppression.  To determine when and how long C3a needs to 
be present for suppression of the Fc polyclonal response, it was added from day 0  to 
day 5  of culture and  the ensuing polyclonal antibody response measured  on  day 6. 
The results indicate that by day 2, the PBL are no longer susceptible to the suppressive 
effects of C3a  (Fig. 6), indicating that C3a acts at an early phase of the response. As 
a  control, C3ades ~g-77 was added at the designated times and as shown in Figs.  1 and 
2, no suppression was observed. 
Requirement for a  Carboxypeptidase Inhibitor  in  Cultures Containing Serum.  Up  to  this 
point, we used cultures containing either fetal calf serum or human  plasma in all the 
experiments.  To  measure  optimum  C3a-mediated  suppression  the  addition  of 1418  ANAPHYLATOXIN-MEDIATED REGULATION OF  HUMAN  RESPONSE 
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FIG. 6.  Human PBL (1 X 105 B and 2 X 105 T cells) were cultured with 5/~g/ml of Fc fragments. 
At various  time intervals C3a (0)  (50/~g/ml) or C3aa#8 A~-7; (©)  (50/~g/ml) was added to culture. 
The polyclonal  antibody response was measured on day 6 of culture.  1 mM 2-mercaptomethyl-5- 
guanidinopentanoic acid was present. 
TABL~  III 
Suppression of the Fc Fragment-mediated  Polyclonal Antibody Response of 
Human PBL by Human C3a 
SCP in-  Fc~  C3a§  C3adesAg-77§  Ig-secreting cells/  Sup- 
hibitor*  106 B cells +  SE  pression 
% 
+  +  --  --  1,721 ±  131  0 
+  +  +  --  341 ±  17  80 
+  +  --  +  1,538 +  174  10 
--  +  --  --  1,364 +  96  0 
--  +  +  --  1,415  +  69  0 
--  +  --  +  1,470 +  76  0 
* The serum carboxypeptidase  inhibitor 2-mercaptomethyl-5-guanidinopen- 
tanoic acid was added to a final concentration ofQ.15 #g/ml (1 mM). 
The Fc concentration was 5 #g/ml. 
§ The C3a and C3aa~ A~-V7 concentration was 50 /tg/ml. 
2-mercaptomethyl-5-guanidinopentanoic  acid,  a  serum  carboxy-peptidase  inhibitor 
(19),  is required.  If the  inhibitor  is omitted,  the endogenous  enzyme rapidly  cleaves 
the  terminal  arginine  from  C3a  producing  C3ade8 Arg-77 (33).  To  formally prove that 
the  carboxypeptidase  inhibitor  is  required  for  expression  of  maximal  suppressive 
activity by C3a, human  PBL were cultured  in the presence of Fc fragments  and  C3a 
in serum-containing medium with and without the inhibitor added. Cultures contain- 
ing  the  inhibitor  showed  a  strong  suppression  (80%),  whereas  cultures  lacking  the 
inhibitor showed  no  suppression  (Table  III).  Moreover, addition  of C3ade8 Arg-77 plus 
inhibitor to the cultures had no effect. To determine if a  combination of the inhibitor 
and  C3a  was  responsible  for  suppression,  we  took  advantage  of an  Fc  polyclonal 
system  where serum  was omitted.  Fc fragments  induce  the murine B  cell tumor  line 
BCL1  to proliferate and  secrete antibody  in  the absence  of serum  (Table  III, and  E. 
L.  Morgan,  M.  L.  Thoman,  and  W.  O.  Weigle,  manuscript  in  preparation).  The 
addition  of C3a  to  BCLa  cultures  resulted  in  a  69%  suppression  of the  polyclonal 
antibody  response  (Table  IV).  These  results  indicate  that  suppression  occurs  as  an 
effect of the C3a and not the carboxypeptidase  inhibitor. 
Cellular Level of C3a-mediated Suppression.  As mentioned above, Fc fragments induce EDWARD  L.  MORGAN, WILLIAM O.  WEIGLE, AND TONY  E.  HUGLI  1419 
TABLE  IV 
Suppression of the BCL1 Fc Fragment-mediated Polyclonal Antibody Response by Human C3a 
Ig-secreting cells/108  Suppres- 
BCLI*  T Cells~:  Fc§  C3all  C3aa~ Arg-77¶  BCL1 ±  SE  sion 
% 
+  +  -  -  -  3,500 ±  471  -- 
+  +  +  -  -  14,500 ±  1,967  0 
+  +  +  +  -  4,500 ±  1,210  69 
+  +  +  -  +  14,750 +  2,036  0 
* 1 ×  10  ~ cultured BCLa cells +  2 X 105 adherent cells. 
:~ 1 X 105 cultured T cells. 
§ 250/~g/ml of Fc added. 
II 50 ~g/ml of C3a or C3ad~ Am-77 added. 
TABLE  V 
Inability of C3a to Suppress the Proliferative Response of the 
BCLx  Tumor Line* 
BCL1*  LPS~  Vc§  C3all  [3H]TdR uptake¶  Suppres- 
sion 
cpm/culture ± SE  % 
+  -  -  -  10,469 ±  610  -- 
+  +  -  -  97,407 ±  446  0 
+  +  --  +  108,105 ±  5,586  0 
+  -  -  +  5,778 ±  66  0 
+  -  +  -  151,927 :k 6,424  0 
+  --  +  +  166,350 ±  5,010  0 
* 2  ×  105  BCL1 cells/well were  mixed with  2  ×  105  irradiated,  adherent 
BALB/c cells in serum-free  medium. 
:~ 20 #g/rnl of LPS added. 
§ 100 #g/ml of Fc added. 
[I 50/.tg/ml of C3a added. 
¶ The cultures were harvested on day 2 of culture. 
human  (34)  and murine  (20)  B  cells to proliferate as well as to secrete antibody.  The 
proliferative  response  requires  the  presence  of macrophages  (20,  21),  whereas  the 
polyclonal response  requires both  macrophages  and  T  cells (22-24).  The site of C3a- 
mediated suppression  in the Fc-mediated polyclonal response is not at the level of the 
proliferating  B  cell.  This  is  shown  in  Table  II,  where  C3a  did  not  affect  the  Fc- 
induced  proliferative response of intact  spleen cells. To further explore the effects of 
C3a on B  cells, the B  cell tumor line BCLx was supplemented  with macrophages  and 
cultured  with  Fc fragments  and  C3a.  The  results  in Table  V  indicate  that  C3a  did 
not suppress  the Fc proliferative response.  Moreover, C3a did not suppress  the BCL1 
proliferative  response  to  LPS,  another  B  cell  activator  (Table  V).  These  results,  in 
conjunction  with data obtained with PHA  and  PWM,  indicate that  C3a suppression 
is not at the level of the proliferating T  or B  cell. 
To  ascertain  whether  C3a-mediated  suppression  occurred  at  the  level  of  the 
macrophage,  plasmin  Fc  fragments  were used  as  the stimulating  agent.  It  has  been 
previously reported  that  the requirement  for macrophages  could be bypassed  in  the 
Fc-induced  polyclonal  response  by  use  of  either  Fc  subfragments  (21,  22)  or  by 
plasmin-derived  Fc  fragments  (30).  When  macrophage-depleted  murine  spleen  cells 1420  ANAPHYLATOXIN-MEDIATED  REGULATION  OF  HUMAN  RESPONSE 
Group  Spleen  Plasmin  C3a  C3a 
Cells  Fc  des Arg 
i i  +  +  ~-x~  ~JH//////HHx/XI"  "HXHXHH/~HHXXXXHX"  ~/XX  "  "  "XXXX"  "HX~ 
III  +  +  +  191%1 
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Dkent Anti-TNP  PFC/10  ~ ± SE 
FIG.  7.  Macrophage-depleted murine splenic lymphocytes (6 ×  l0  s) were cultured with 100 y.g/ml 
plasmin-generated Fc  fragments and  50  /~g/ml  of C3a  or  C3adegArg-77.  The  polyclonal  antibody 
response was measured on day 3 of culture. The number in parentheses indicates percent suppression. 
I mM 2-mercaptomethyl-5-guanidinopentanoic acid was present. 
B  T 
Group  Cells  Cells  Factor  Fn  C3a 
I  +  +  +  -  ~.  -/,  ~.  -.  ,~/////t/w////////////~. 
II  +  +  +  +  v///,-/~/M/.-/~  181%) 
I I I  +  +  +  ~.-  -/.  -/////.,  ,H////////1//,  ~/////////~ 
IV  +  +  +  +  "////.'.'//t//,'/H///HM////////W///~  (0%} 
260  460  660  86030'00'2'00  ~'00 
Ig Secreting  CelN 10  ~ B  Cells ± SE 
Fro.  8.  Human  PBL B cells (1  X  105) were cultured with T  cells (2  ×  105) or Sephadex G-100- 
purified, PHA-induced factor (25/.tl)  plus 5 ~g/ml Fc fragments. C3a was added to certain cultures 
at  50  /tg/ml.  The  polyclonal  antibody  response was  measured  on  day  6  of culture.  1 mM  2- 
mercaptomethyl-5-guanidinopentanoic acid was present. 
TABL~  VI 
Ability of C3a-treated T Cells to Suppress the Human Fc Fragment-induced 
Polyclonal Antibody Response 
Incubation*  Fc:~  Ig-secreting cells/10  e  Suppres- 
B cells ±  SE  sion 
h  % 
0  -  134 +_  12 
0  +  1,017 ±  50 
C3a,  0.5  +  192 ±  56  82 
Medium,  0.5  +  1,283 ±  68  0 
C3a,  1.0  +  158 ±  19  85 
Medium,  1.0  +  1,142 ±  130  0 
C3a,  2.0  +  175 +  6  83 
Medium,  2.0  +  1,234 +  25  0 
* T  cells were  incubated with  50 /Lg/ml C3a  for the  times indicated  with 
inhibitor  (2-mercaptomethyl-5-guanidinopentanoic acid), washed, and cul- 
tured with B cells in the absence of inhibitor for 6 d. 
Fc concentration was 5 ~g/ml. 
were  cultured  with  plasmin  Fc  fragments,  a  polyclonal  antibody  response  was 
generated  (Fig.  7).  Addition  of C3a  to  plasmin  Fc  cultures  resulted  in  a  dramatic 
suppression  (91%)  of polyclonal  antibody  response  (Fig.  7).  In  contrast,  C3adesgxg-77 
was unable  to suppress the plasmin  Fc polyclonal  response. These  results indicate  that 
C3a-mediated  suppression  is specific and  occurs  in the absence  of macrophages. 
The  role  of the  T  cell  in  C3a-mediated  suppression  of the  immune  response  was 
examined  using  the  Fc  polyclonal  model.  It  has  been  established  that  the  T  cell EDWARD L.  MORGAN, WILLIAM O.  WEIGLE, AND TONY  E.  HUGLI  1421 
TABLE VII 
Inability of Anti-Lyt-2.2 Treatment to Prevent C3a Suppression of the Murine 
Fc Fragment-mediated  Polyclonal Antibody Response 
Direct anti- 
Spleen cell treatment  Fc*  C3a:j:  TNP PFC/10  ~  Suppres-  sion  4- SE 
% 
None  -  -  14 4- 4  -- 
None  +  -  119 ±  3  0 
None  +  +  14 4- 1  100 
Anti-Lyt-2.2  -  -  24 +  1  -- 
Anti-Lyt-2.2  +  -  168 4- 11  0 
Anti-Lyt-2.2  +  +  24 + 5  100 
* 250 ~g/ml of Fc added. 
~: 50 ~g/ml of C3a added. The concentration of 2-mercaptomethyl-5-guanidi- 
nopentanoic acid was 1 raM. 
requirement  in  the  murine  Fc  polyclonal antibody  response  can  be  replaced by  a 
factor derived from  either concanavalin  A-  (23)  or Fc fragment-  (24)  stimulated T 
cells. This finding has been confirmed for a  human  Fc polyclonal model in that the 
Sephadex G-100-purified factor derived from PHA-stimulated human PBL is capable 
of  replacing  T  cells  in  the  human  PBL  polyclonal  response  (Fig.  8,  group  III). 
Addition of C3a to human cultures failed to suppress the response (Fig. 8, groups III 
and IV). As a  control, cultures with T  cells were also supplemented with C3a and the 
ensuing response was measured  (Fig. 8, groups I  and II). These results indicate that 
the  C3a-mediated  suppression  of  the  immune  response  occurs  through  a  T  cell 
population.  As  described  above,  T  cells are  required  for  the  Fc  fragment-induced 
murine polyclonal responses as well as the human  PBL responses. 
To determine the length of time C3a had to be in contact with T  cells to induce 
suppression,  purified  human  T  cells  were  incubated  with  C3a  in  the  presence  of 
inhibitor, washed, and added to B cell populations in the absence of inhibitor and the 
polyclonal antibody response measured.  The results in Table VI indicate that 0.5  h 
is sufficient time for C3a to induce an 82%  suppression of the human  Fc polyclonal 
antibody response. Moreover, the suppression is not a  result of C3a carryover because 
the residual C3a bound to T  cells would be converted to the inactive C3aaes A~g-77 form 
by serum carboxypeptidase in the absence of an inhibitor. Similar results were found 
using C3a-treated murine splenic T  cells (data not shown). 
The Lyt phenotype of the T  cell in the murine Fc polyclonal resporise is Lyt-l+2  - 
(24). Therefore, the presence of a potential Lyt-1-2  + suppressor T  cell was investigated. 
Intact  murine  spleen  was  treated  with  anti-Lyt  2.2  before  stimulation  with  Fc 
fragments. Depletion of Lyt-2  + cells had no effect on the polyclonal antibody response 
(Table VII). When C3a was included in these cultures, the response was completely 
suppressed (Table VI), indicating that the C3a-induced suppression was not depend- 
ent on the presence of an existing Lyt-2  + suppressor cell. 
Discussion 
C3a is a  complement activation factor from human serum that has the capacity to 
suppress both specific and nonspecific humoral  immune  responses. Addition of C3a 1422  ANAPHYLATOXIN-MEDIATED REGULATION OF  HUMAN RESPONSE 
to cultures  of human  PBL or murine splenic  lymphocytes results  in  suppression  of 
both  the  anti-SRBC  response  and  the  Fc  fragment-mediated  polyclonal  antibody 
response. Moreover, the Fc polyclonal antibody response of the murine B cell tumor 
BCL1 was also suppressed. In contrast to these results, mitogen- and antigen-induced 
T  and B cell proliferative responses were not affected by C3a. Concentrations of C3a 
that are 10-fold greater than those required to fully suppress the anti-SRBC response 
had  no  effect  on  the  proliferative  response  induced  by  tetanus  toxoid.  Similar 
concentrations  of C3a  failed  to  suppress  the  nonspecific  proliferative  responses  to 
PHA or PWM. In addition, B cell proliferation induced by Fc fragments or LPS was 
unaffected  by  C3a.  The  inability  of C3a  to  suppress  either  antigen-  or  mitogen- 
induced proliferative responses is in contrast to the results of Needleman et al.  (18). 
These  authors  reported  that  a  small  fragment  derived  from trypsin  digests  of C3, 
presumably C3a, was capable of suppressing both antigen- and mitogen-induced PBL 
proliferative responses. The reason(s) for our inability to suppress mitogenic responses 
is currently unknown. Several possibilities could account for the discrepancies:  (a) the 
C3a prepared from serum is exposed to extremely low pH conditions during isolation 
and may be physically different from that obtained by Needleman (18)  from purified 
C3;  or  (b)  multiple  C3  factors  may be present  in  their  preparation.  Studies  using 
synthetic  analogue  peptides  of C3a  that  are  biologically  active  in  other  systems 
indicate that antibody, but not proliferative, responses are suppressed by C3a peptides 
(E. L. Morgan, W. O. Weigle, and T. E. Hugli, manuscript in preparation). 
Immune suppression  mediated  by C3a occurs at  an early phase in  the antibody 
response. This conclusion came from our observation that when C3a was added on 
day  0,  maximal  suppression  was  achieved;  however,  when  added  on  day  1,  only 
marginal suppression was observed. In addition,  interaction of purified T  cells with 
C3a for as little as 30 min results in a pronounced suppression. Moreover, the positive 
action of the carboxypeptidase inhibitor dictates that C3a must act relatively early in 
the response because the compound is a competitive inhibitor and protects the factor 
from conversion for only a few hours. 
The carboxy terminal arginine is essential for C3a to exhibit  its immunosuppres- 
sive  properties.  When  the  terminal  arginine  is  removed  from  C3a  the  resulting 
C3ades Arg-77 molecule is nonsuppressive. These results correspond to the tactyphylactic 
properties of C3a (17). Taken together, our results indicate that the terminal arginine 
of C3a  is  at  the  active  center  and  is  required  for  producing  immunosuppressive 
actions. Therefore, the serum carboxypeptidase serves the same role in controlling the 
immunosuppressive activities of C3a as it does in restricting spasmogenic action. Work 
is currently in progress to confirm that synthetic peptide analogues of C3a that exhibit 
the biological attributes of this factor are also capable of immunosuppression  (42). 
T  lymphocytes are the target of C3a-mediated suppression of the immune response. 
Substitution  of the T  cells by a  soluble T  cell factor in  the Fc polyclonal antibody 
response abrogates the suppressive response of C3a. This is an important  finding in 
that  C3a  is  incapable  of  suppressing  either  antigen-  or  mitogen-induced  T  cell 
proliferation. The action of C3a on T  cells could be through an interference with the 
T  cell-macrophage interaction as proposed for other C3 cleavage products (1 1). This 
pathway  is  presumably not  affected,  however,  because  when  macrophages  are  re- 
moved  suppression  still  occurs.  In  the  case  of the  plasmin  Fc-induced  polyclonal 
antibody response,  the  response is T  cell  dependent,  but  unlike  Fc activation,  it  is EDWARD L.  MORGAN, WILLIAM O.  WEIGLE, AND TONY E.  HUGLI  1423 
independent of macrophages (30).  C3a suppresses the plasmin Fc polyclonal response 
as efficiently as it does the Fc-mediated response. Additional evidence for the T  cell 
being the  target  of C3a-mediated  suppression  is  drawn  from the  observation  that 
incubation of purified T  cells with C3a renders the T  cells incapable of helping in the 
Fc-induced  polyclonal  antibody  response.  Moreover,  C3a  has  been  found  not  to 
suppress  in  vitro antibody responses to the T  cell-independent  antigens,  TNP-LPS 
and TNP-Ficoll (E. L. Morgan, unpublished observations). C3a-mediated suppression 
does  not  appear  to  involve  the  activation  of existing  suppressor  T  cells  because 
depletion  of Lyt-2  ÷ cells has no effect on the level of suppressor cells.  This finding 
does not rule out the possibility that a  suppressor cell is being generated in culture, 
however. Because C3a acts early in polyclonal and specific antibody responses, the 
possibility  exists  that  C3a  could  act  upon  suppressor  precursor  cells  (Lyt-l÷2-), 
inducing the formation of suppressor cells  (44).  Preliminary data indicate that C3a 
does indeed induce the production of suppressor T ceils that are capable of suppressing 
both the Fc polyclonal and anti-SRBC responses (E. L. Morgan, W. O. Weigle, and 
T. E. Hugli, manuscript in preparation). 
C3a was also unable to suppress the LPS- or Fc fragment-mediated proliferative 
responses. The Fc polyclonal response results from the delivery of two signals to the 
B  cell  (22).  The first is a  proliferative signal that stimulates the B  cells,  and in the 
presence of a  second  T  cell-derived signal  they may be differentiated  to antibody- 
secreting cells.  The  B  cell  proliferative phase  is  an  integral  part  of the  polyclonal 
response without  which  little or no antibody  is  produced.  The inability of C3a to 
suppress  the  Fc  proliferative  response  in  the  presence  or  absence  of T  cells  gives 
further support to the hypothesis that (23a exerts its action at the level of the helper 
T  cell. 
The  mechanism  by which  C3a  interferes  with  helper  T  cell  action  is  currently 
unknown.  C3a does not interfere with T  cell proliferation or the delivery of the (Fc) 
T  cell-replacing  factor  signal  to  the  B  cell  because  Cl3a  was  unable  to  suppress 
responses mediated by soluble cell factors when substituted  for T  cells. If C3a acted 
by combining with the T  cell factor or prevented the factor from interacting with the 
proliferating B cell, then suppression should occur. 
The amount of human C3a needed to suppress human PBL responses was ~ 100- 
fold lower than that needed to suppress murine immune responses. It is not currently 
known whether the species differences are expressions of receptor specificity or of true 
variations in sensitivity between human and murine helper T  cells. It is clear that the 
level of C3a required to suppress the antibody response falls well within the physiologic 
range of humans. Significant suppression of human PBL responses was observed at a 
C3a concentration of 0.1-1/tg/ml, a  level well below the potential concentration  of 
50-60 #g/ml C3a generated by maximal human C3 conversion. 
The physiological significance of C3a-mediated regulation of the humoral immune 
response is currently a matter of speculation. In contrast to the results obtained with 
C3a,  C5a was found  to augment  the  Fc-mediated polyclonal  antibody response of 
human PBL (E. L. Morgan, W. O. Weigle, and T. E. Hugli, manuscript in prepara- 
tion). Invasion of the body by a foreign organism results in the synthesis of antibody 
and the triggering of the complement cascade. The presence of C3a and C5a in the 
microenvironment  where  B  cells,  T  ceils,  and  macrophages  are  interacting  could 
influence  the  level of antibody produced.  Although  C3a  is  relatively short-lived in 1424  ANAPHYLATOXIN-MEDIATED  REGULATION OF HUMAN RESPONSE 
circulation, that the suppressor action is mediated by C3a-induced suppressor T  cells 
lends validity to its potential action in  vivo. In addition, the presence of the serum 
carboxypeptidase  could  act  as  a  control  mechanism  for  C3a  immunosuppressive 
action. Thus, in addition to its other biological activities, the anaphylatoxin may be 
involved in controlling the amount of antibody produced during an  infection. The 
action of C3a in conjunction with other factors could serve as a  complex regulatory 
circuit in controlling an ongoing antibody response. 
Summary 
The  C3a  fragment  of the  third  component  of complement  was  found  to  have 
immunosuppressive  properties.  C3a  is  capable  of  suppressing  both  specific  and 
polyclonal antibody responses. In contrast, C3a had no effect on antigen- or mitogen- 
induced B or T  cell proliferative responses. The carboxy-terminal arginine is essential 
for C3a to exhibit  its  immunosuppressive  properties.  The  serum  carboxypeptidase 
inhibitor 2-mercaptomethyl-5-guanodinopentanoic acid, which prevents cleavage of 
the terminal arginine that would produce C3ades Arg-77, allowed us to assay the effects 
of C3a  on  in  vitro  immune  response  systems  where  serum  is  required.  When  the 
terminal arginine is removed from C3a, the resulting C3aaes Arg-77 molecule is nonsup- 
pressive.  Helper T  lymphocytes are  the  target  of C3a-mediated suppression  of the 
immune  response.  Substitution  of T  cells  by  soluble  T  cell  factors  was  found  to 
abrogate the C3a suppressive activity. 
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